GTx is conducting two phase III studies of enobosarm, a selective androgen receptor modulator (SARM) in lung-cancer related muscle wasting. The company's official guidance is to report results in the third quarter but the data are expected to be announced in August.
The survey says: The enobosarm studies will fail, with 39 percent of respondents predicting negative results. Almost the same number of people -- 38 percent -- had no opinion on the outcome of the studies; while only 24 percent predicted positive results. I predict failure for enobosarm's clinical trials, in line with a recent , bearish column about the drug and its previously conducted phase II study.
Here's the pie chart:My panel of 12 professional healthcare investors are equally unimpressed with GTx and enobosarm. Seventy-five percent predicted negative results versus 17 percent predicting a positive outcome. One investor chose not to respond. Here's a look at GTx's stock chart for the past six months: GTXI data by YCharts
GTx's short interest is relatively modest at just over 3 million shares. -- Reported by Adam Feuerstein in Boston. Follow Adam Feuerstein on Twitter.